A Randomised Active-Controlled Double-Blind and Open Label Extension Study to Evaluate the Efficacy, Long-term Safety and Tolerability of TP05 3.2 g/day for the Treatment of Active Ulcerative Colitis (UC)
Latest Information Update: 13 Jan 2022
At a glance
- Drugs Mesalazine (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Acronyms Precision-UC
- Sponsors Tillotts Pharma
- 11 Nov 2017 According to a Tillotts Pharma media release, this trial was led by Prof. Geert D Haens, University of Amsterdam.
- 11 Nov 2017 According to a Tillotts Pharma media release, full results were published in the international journal Alimentary Pharmacology & Therapeutics.
- 01 Aug 2017 Primary endpoint has been met. (Clinical and endoscopic remission) as per results published in the Alimentary Pharmacology and Therapeutics